Solid Biosciences to Participate at Upcoming Investor Conferences

Rhea-AI Summary

Solid Biosciences (Nasdaq: SLDB) announces participation of Dr. Joel Schneider and Dr. Carl Morris at the SVB Leerink CybeRx Series and Chardan's 5th Annual Genetic Medicines Conference. The fireside chat from the Chardan conference will be available via live webcast on October 5, 2021, at 2:30 p.m. ET on the company's investor relations website. Solid Biosciences is committed to developing transformative therapies for Duchenne muscular dystrophy and is advancing its lead gene therapy candidate, SGT-001.

CAMBRIDGE, Mass., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Joel Schneider, Ph.D., Chief Operating Officer, and Carl Morris, Ph.D., Chief Scientific Officer, will participate at the SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases & Genetic Medicines 1x1 Event and Chardan's 5th Annual Genetic Medicines Conference.

A live webcast of management’s fireside chat at the Chardan conference will be available on the Company’s investor relations website on Tuesday, October 5, 2021 at 2:30 p.m. ET, under the Events page accessible here: https://investors.solidbio.com/news-and-events/events. A replay will be available on the Company's website following the event.

About Solid Biosciences
Solid Biosciences is a life sciences company focused on advancing transformative treatments to improve the lives of patients living with Duchenne. Disease-focused and founded by a family directly impacted by Duchenne, our mandate is simple yet comprehensive – work to address the disease at its core by correcting the underlying mutation that causes Duchenne with our lead gene therapy candidate, SGT-001. For more information, please visit www.solidbio.com.

Investor Contact:
Caitlin Lowie
Solid Biosciences
607-423-3219
Clowie@solidbio.com

David Carey
FINN Partners
212-867-1768
David.Carey@finnpartners.com

Media Contact:
Erich Sandoval
FINN Partners
917-497-2867
Erich.Sandoval@finnpartners.com

FAQ

When will Solid Biosciences participate in the SVB Leerink CybeRx Series?

Solid Biosciences will participate in the SVB Leerink CybeRx Series on September 20, 2021.

What is the date and time of the webcast for the Chardan conference?

The webcast for the Chardan conference will be held on October 5, 2021, at 2:30 p.m. ET.

Where can I find the webcast of the Solid Biosciences fireside chat?

The webcast can be found on Solid Biosciences' investor relations website under the Events page.

What is the focus of Solid Biosciences' research?

Solid Biosciences is focused on advancing therapies for Duchenne muscular dystrophy.

What is the lead gene therapy candidate of Solid Biosciences?

The lead gene therapy candidate of Solid Biosciences is SGT-001.